Verition Fund Management’s Artelo Biosciences, Inc. Warrant ARTLW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-27,299
Closed -$440 3363
2024
Q1
$440 Hold
27,299
﹤0.01% 2742
2023
Q4
$1.09K Hold
27,299
﹤0.01% 2279
2023
Q3
$1.32K Hold
27,299
﹤0.01% 2293
2023
Q2
$2.21K Hold
27,299
﹤0.01% 2146
2023
Q1
$1.78K Hold
27,299
﹤0.01% 2107
2022
Q4
$1.09K Sell
27,299
-7,701
-22% -$641 ﹤0.01% 2040
2022
Q3
$4K Hold
35,000
﹤0.01% 2952
2022
Q2
$166K Hold
35,000
﹤0.01% 1990
2022
Q1
$6K Hold
35,000
﹤0.01% 2659
2021
Q4
$6K Hold
35,000
﹤0.01% 2497
2021
Q3
$8K Hold
35,000
﹤0.01% 1840
2021
Q2
$11K Hold
35,000
﹤0.01% 1843
2021
Q1
$15K Hold
35,000
﹤0.01% 1506
2020
Q4
$9K Hold
35,000
﹤0.01% 1056
2020
Q3
$3K Hold
35,000
﹤0.01% 1026
2020
Q2
$4K Hold
35,000
﹤0.01% 1036
2020
Q1
$2K Hold
35,000
﹤0.01% 561
2019
Q4
$10K Hold
35,000
﹤0.01% 1032
2019
Q3
$20K Hold
35,000
﹤0.01% 1005
2019
Q2
$30K Buy
+35,000
New +$30.5K ﹤0.01% 1023

Verition Fund Management's ARTLW Position: Q2 2024 in Review

Verition Fund Management sold out of Artelo Biosciences, Inc. Warrant (ARTLW) in Q2 2024, closing a stake of 27,299 shares — an estimated $440 sold.

Verition Fund Management first reported a position in ARTLW in Q2 2019 and held it in 20 quarters. The position peaked at $166K in Q2 2022. 0 funds tracked by Wall St. Rank hold ARTLW as of Q2 2024.

  • Verition Fund Management reported no remaining Artelo Biosciences, Inc. Warrant position as of Q2 2024 after selling out during the quarter.
  • Verition Fund Management sold 27,299 Artelo Biosciences, Inc. Warrant shares in Q2 2024, an estimated $440.
  • Verition Fund Management first reported a position in Artelo Biosciences, Inc. Warrant in Q2 2019 and held it in 20 quarters.
  • Verition Fund Management's Artelo Biosciences, Inc. Warrant position peaked at $166K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Artelo Biosciences, Inc. Warrant as of Q2 2024.

Based on Verition Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.